Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial

Abstract Background: Aclidinium bromide is an inhaled, long-acting muscarinic antagonist currently in development for the treatment of chronic obstructive pulmonary disease. Renal impairment may affect drug clearance. Objective: This study was conducted to evaluate the pharmacokinetic (PK) parameter...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2010-09, Vol.32 (10), p.1798-1812
Hauptverfasser:	Schmid, Karin, MD, Pascual, Silvia, MSc, Gil, Esther Garcia, MD, Ortiz, Stephan, RPh, PhD, Jansat, Josep M., PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	aclidinium bromide Administration, Inhalation Adolescent Adult Aged Biological and medical sciences Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease, asthma COPD Creatinine Diabetes Drug dosages Female Humans Internal Medicine International conferences Kidney Function Tests Male Medical Education Medical sciences Metabolic Clearance Rate Middle Aged Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Muscarinic Antagonists - blood Muscarinic Antagonists - pharmacokinetics Muscarinic Antagonists - urine Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Pharmacokinetics Pharmacology. Drug treatments Pneumology Pulmonary Disease, Chronic Obstructive - drug therapy Renal failure renal insufficiency Renal Insufficiency - blood Renal Insufficiency - metabolism Renal Insufficiency - urine safety Severity of Illness Index Tropanes - administration & dosage Tropanes - adverse effects Tropanes - blood Tropanes - pharmacokinetics Tropanes - urine Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!